Literature DB >> 26451317

COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.

Ze-Lei Li1, Shu-Biao Ye1, Li-Yin OuYang1, Han Zhang1, Yu-Shan Chen2, Jia He1, Qiu-Yan Chen3, Chao-Nan Qian3, Xiao-Shi Zhang1, Jun Cui4, Yi-Xin Zeng5, Jiang Li1.   

Abstract

The expansion of myeloid-derived suppressor cells (MDSCs) is a common feature of cancer, but its biological roles and molecular mechanism remain unclear. Here, we investigated a molecular link between MDSC expansion and tumor cell metastasis in nasopharyngeal carcinoma (NPC). We demonstrated that MDSCs expanded and were positively correlated with the elevated tumor COX-2 expression and serum IL-6 levels in NPC patients. Importantly, COX-2 and MDSCs were poor predictors of patient disease-free survival (DFS). Knocking down tumor COX-2 expression hampered functional TW03-mediated-MDSC cell (T-MDSC) induction with IL-6 blocking. We identified that T-MDSCs promoted NPC cell migration and invasion by triggering the epithelial-mesenchymal transition (EMT) on cell-to-cell contact, and T-MDSCs enhanced tumor experimental lung metastasis in vivo. Interestingly, the contact between T-MDSCs and NPC cells enhanced tumor COX-2 expression, which subsequently activated the β-catenin/TCF4 pathway, resulting in EMT of the cancer cells. Blocking transforming growth factor β (TGFβ) or inducible nitric oxide synthase (iNOS) significantly abolished the T-MDSC-induced upregulation of COX-2 and EMT scores in NPC cells, whereas the administration of TGFβ or L-arginine supplements upregulated COX-2 expression and EMT scores in NPC cells. These findings reveal that COX-2 is a key factor mediating the interaction between MDSCs and tumor cells, suggesting that the inhibition of COX-2 or MDSCs has the potential to suppress NPC metastasis.

Entities:  

Keywords:  COX-2; myeloid-derived suppressor cells; nasopharyngeal carcinoma

Year:  2015        PMID: 26451317      PMCID: PMC4590030          DOI: 10.1080/2162402X.2015.1044712

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  58 in total

1.  Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells.

Authors:  Claudia Bocca; Francesca Bozzo; Stefania Cannito; Maurizio Parola; Antonella Miglietta
Journal:  Mol Carcinog       Date:  2011-08-31       Impact factor: 4.784

2.  Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression.

Authors:  R A Soo; J Wu; A Aggarwal; Q Tao; W Hsieh; T Putti; K B Tan; J S W Low; W L Soon; Y F Lai; B Mow; S Hsu; K S Loh; L Tan; P Tan; B-C Goh
Journal:  Ann Oncol       Date:  2006-09-28       Impact factor: 32.976

3.  PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.

Authors:  Natasa Obermajer; Ravikumar Muthuswamy; Kunle Odunsi; Robert P Edwards; Pawel Kalinski
Journal:  Cancer Res       Date:  2011-10-24       Impact factor: 12.701

4.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

Review 5.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

6.  URG11 mediates hypoxia-induced epithelial-to-mesenchymal transition by modulation of E-cadherin and beta-catenin.

Authors:  Rui Du; Chen Huang; Qian Bi; Ying Zhai; Lin Xia; Jie Liu; Shiren Sun; Daiming Fan
Journal:  Biochem Biophys Res Commun       Date:  2009-11-11       Impact factor: 3.575

7.  Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.

Authors:  Jinpu Yu; Weijiao Du; Fang Yan; Yue Wang; Hui Li; Shui Cao; Wenwen Yu; Chun Shen; Juntian Liu; Xiubao Ren
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

Review 8.  Myeloid-derived suppressor cell heterogeneity in human cancers.

Authors:  Samantha Solito; Ilaria Marigo; Laura Pinton; Vera Damuzzo; Susanna Mandruzzato; Vincenzo Bronte
Journal:  Ann N Y Acad Sci       Date:  2014-06       Impact factor: 5.691

Review 9.  The mechanism of the anticancer function of M1 macrophages and their use in the clinic.

Authors:  Xing-Qing Pan
Journal:  Chin J Cancer       Date:  2012-11-13

10.  Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer.

Authors:  Chris P Verschoor; Jennie Johnstone; Jamie Millar; Michael G Dorrington; Mojtaba Habibagahi; Alina Lelic; Mark Loeb; Jonathan L Bramson; Dawn M E Bowdish
Journal:  J Leukoc Biol       Date:  2013-01-22       Impact factor: 4.962

View more
  42 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

2.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

Review 3.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

4.  STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion.

Authors:  Chuan-Xia Zhang; Shu-Biao Ye; Jian-Jiao Ni; Ting-Ting Cai; Yi-Na Liu; Dai-Jia Huang; Hai-Qiang Mai; Qiu-Yan Chen; Jia He; Xiao-Shi Zhang; Yi-Xin Zeng; Jiang Li; Jun Cui
Journal:  Cell Death Differ       Date:  2019-02-28       Impact factor: 15.828

5.  CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.

Authors:  H Zhang; Y-L Ye; M-X Li; S-B Ye; W-R Huang; T-T Cai; J He; J-Y Peng; T-H Duan; J Cui; X-S Zhang; F-J Zhou; R-F Wang; J Li
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

Review 6.  Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies.

Authors:  Peng-Fei Wang; Si-Ying Song; Ting-Jian Wang; Wen-Jun Ji; Shou-Wei Li; Ning Liu; Chang-Xiang Yan
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

7.  Overexpression of IGFBP3 is associated with poor prognosis and tumor metastasis in nasopharyngeal carcinoma.

Authors:  Lili Bao; Hao Liu; Bo You; Miao Gu; Si Shi; Ying Shan; Li Li; Jing Chen; Yiwen You
Journal:  Tumour Biol       Date:  2016-09-22

8.  Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer.

Authors:  Rong Yang; Ting-Ting Cai; Xiao-Jun Wu; Yi-Na Liu; Jia He; Xiao-Shi Zhang; Gang Ma; Jiang Li
Journal:  Immunology       Date:  2018-06-11       Impact factor: 7.397

Review 9.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

10.  Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?

Authors:  Ila Datar; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2016-04-13       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.